DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer

British Journal of Cancer

Volumn 89, Issue 4, 2003, Pages 666-671

  MacGrogan, G ^a   Rudolph, P ^b   De Mascarel, I ^a   Mauriac, L ^a   Durand, M ^a   Avril, A ^a   Dilhuydy, J M ^a   Robert, J ^a   Mathoulin Pelissier S ^a   Picot, V ^a   Floquet, A ^a   Sierankowski, G ^a   Coindre, J M ^a  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Anthracyclines; Breast cancer; Her 2 neu; Primary chemotherapy; Topoisomerase II

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; EPIRUBICIN; ESTROGEN RECEPTOR; ISOENZYME; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN C; PROGESTERONE RECEPTOR; PROTEIN P53; THIOTEPA; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR VOLUME; BREAST TUMOR; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0043236239     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601185     Document Type: Article

References (39)

1. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES (1996a) Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 319 (Part 1): 307-313
2. Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES (1996b) Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumour cells sensitises the cells to etoposide. Oncol Res 8: 101-110
3. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J, Bignon YJ (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896-900
4. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232
5. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J (1996) Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (> 10 involved lymph nodes) treated with high-dose chemotherapy and autologous haematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2: 1509-1513
6. Clahsen PC, van de Velde, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM (1998) p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16: 470-479
7. de Mascarel I, Soubeyran I, Mac-Grogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM (1995) Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Concordance with biochemical assay and prognostic significance. Appl Immunohistochem 3: 222-231
8. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS (2000) Topoisomerase II alpha expression in breast cancer: correlation with outcome variables. Mod Pathol 13: 542-547
9. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR (2003) Resistance mechanisms of gastrointestinal malignancies - why does chemotherapy fail?. Int J Colorectal Dis, in press
10. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90: 3231-3235
11. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ (1998) Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267-2273
12. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J (1996) Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073-2082
13. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847
14. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O, Parwaresch R (1997) Detection of human topoisomerase II alpha in cell lines and tissues: characterisation of five novel monoclonal antibodies. J Histochem Cytochem 45: 251-263
15. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P (2002) Culprit and victim - DNA topoisomerase II. Lancet Oncol 3: 235-243
16. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM (1995) Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36: 71-81
17. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM (1996a) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465
18. MacGrogan G, Soubeyran I, de Mascarel I, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM (1996b) Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas. Appl Immunohistochem 4: 219-227
19. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52
20. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266
21. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM (1997) Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917-922
22. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA (1992) DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681-683
23. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370
24. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, Parwaresch R (1999a) Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 55: 61-71
25. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R, Alm P (1999b) Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 187: 207-216
26. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL (1996a) Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 73: 1518-1524
27. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F (1996b) p53 regulates the minimal promoter of the human topoisomerase II alpha gene. Nucleic Acids Res 24: 4464-4470
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
29. Stacey DW, Hitomi M, Chen G (2000) Influence of cell cycle and oncogene activity upon topoisomerase II alpha expression and drug toxicity. Mol Cell Biol 20: 9127-9137
30. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 61: 5345-5348
31. Tannock I (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62: 1117-1133
32. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360
33. Tuccari G, Rizzo A, Giuffre G, Barresi G (1993) Immunocytochemicai detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features. Virch Arch A Pathol Anat Histopathol 423: 51-55
34. Vassetzky YS, Alghisi GC, Roberts E, Gasser SM (1996) Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. Br J Cancer 73: 1201-1209
35. Vincent-Salomon A, Carton M, Freneaux P, Palangie T, Beuzeboc P, Mouret E, de Cremoux P, Coue O, Zafrani B, Nicolas A, Clough K, Fourquet A, Pouillart P, Sastre-Garau X (2000) ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 36: 586-591
36. Withoff S, de Vries EG, Keith WN, Nienhuis EF, van der Graaf WT, Uges DR, Mulder NH (1996a) Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer 74: 1869-1876
37. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH, de Vries EG (1996b) Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74: 502-507
38. Wolff AC, Davidson NE (2000) Primary systemic therapy in operable breast cancer. J Clin Oncol 18: 1558-1569
39. Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES (1999) Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59: 4618-4624